1. Home
  2. IVR vs ANNX Comparison

IVR vs ANNX Comparison

Compare IVR & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo INVESCO MORTGAGE CAPITAL INC

IVR

INVESCO MORTGAGE CAPITAL INC

HOLD

Current Price

$7.58

Market Cap

732.4M

Sector

Real Estate

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.26

Market Cap

812.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IVR
ANNX
Founded
2008
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
732.4M
812.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
IVR
ANNX
Price
$7.58
$5.26
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$8.25
$16.50
AVG Volume (30 Days)
2.8M
4.7M
Earning Date
04-30-2026
05-11-2026
Dividend Yield
17.80%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$150.63
N/A
Revenue Next Year
N/A
$16,320.74
P/E Ratio
$6.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.10
$2.03
52 Week High
$9.50
$7.18

Technical Indicators

Market Signals
Indicator
IVR
ANNX
Relative Strength Index (RSI) 35.40 44.36
Support Level $7.13 $4.66
Resistance Level $7.93 $5.65
Average True Range (ATR) 0.16 0.50
MACD -0.04 -0.09
Stochastic Oscillator 6.06 15.12

Price Performance

Historical Comparison
IVR
ANNX

About IVR INVESCO MORTGAGE CAPITAL INC

Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: